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Introduction
Parkinson’s disease (PD) is a neurodegenerative asso-
ciated with a significant, negative impact on quality of
life, health care and societal costs . As the condition
progresses the burden of disease in PD increases. Earlier
identification of PD could provide the opportunity to
intervene earlier, with evidence that this can delay the
onset of the disease. Currently though an early identifi-
cation test for PD does not exist. The aim of this work
is to establish the feasibility and value of identifying bio-
markers in PD which could form the basis of an early
identification test.
Method
A decision analytic model was developed to determine the
lower threshold of sensitivity and specificity that the test
would require to be cost-effective compared to current
practice. The model simulates the incidence and progres-
sion of PD over 10 years, with earlier identification and
treatment stalling disease progress. Extensive probabilistic
and deterministic sensitivity analysis was conducted as
well as an analysis of the extra value of perfect information
(EVPI).
Results
For a willingness to pay for a quality adjusted life year
(QALY) gained of £30,000, the new test would need to
have minimum sensitivity of 0.8 and a specificity of 0.7.
At these values there was a 52% probability that the test
is cost-effective. Given the potential benefits and the
significant uncertainty in the model, the EVPI suggests
that investment into further research in this area could
be of value.
Conclusion
A test for the early detection of PD that is cost-effective
appears to be feasible and worth the additional investment
required.
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